Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company’s new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Nymox has drug technology for other indications such as E. coli infection, Alzheimer’s disease, oncology, and infectious disease.
BPH is a chronic condition that is a common affliction of older men. There is an unmet medical need for an effective treatment for BPH without the side effects associated with currently approved drugs or the complications associated with surgical procedures.
NX-1207 is administered by a urologist in an office setting without the need for anaesthetics or sedation or for catheterization. Patients report little or no pain or discomfort from the procedure. Open label follow-up studies have shown evidence of long lasting benefit from NX-1207 treatment with a significant proportion of men who received a single dose of NX-1207 reporting maintained improvement in BPH symptoms without other treatments for up to five years or more.
BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.
The Company offers NicAlert® and TobacAlert® tests for measuring tobacco product exposure.
Nymox’s stock is traded on NASDAQ under the symbol NYMX. The Company has two subsidiaries, Nymox Corp. and Serex Inc., and facilities in Hasbrouck Heights, NJ and Montreal, QC.